Cargando…

Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy

BACKGROUND: Control of chemotherapy-induced nausea is still incomplete, regardless of adherence to the antiemetic guideline. The present study was designed to assess the control rates of nausea and vomiting in the outpatient chemotherapy clinic and to determine risk factors for nausea. METHODS: A si...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iihara, Hirotoshi, Fujii, Hironori, Yoshimi, Chiaki, Yamada, Maya, Suzuki, Akio, Matsuhashi, Nobuhisa, Takahashi, Takao, Yoshida, Kazuhiro, Itoh, Yoshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824820/ https://www.ncbi.nlm.nih.gov/pubmed/26475354 http://dx.doi.org/10.1007/s10147-015-0908-2

Ejemplares similares

Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens
por: Iihara, Hirotoshi, et al.
Publicado: (2016)

Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome
por: Iihara, Hirotoshi, et al.
Publicado: (2018)

Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapy
por: Fujii, Hironori, et al.
Publicado: (2022)

Real-world data of the association between quality of life using the EuroQol 5 Dimension 5 Level utility value and adverse events for outpatient cancer chemotherapy
por: Hirose, Chiemi, et al.
Publicado: (2020)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer
por: Fujii, Hironori, et al.
Publicado: (2018)

One-Day Versus Three-Day Dexamethasone with NK1RA for Patients Receiving Carboplatin and Moderate Emetogenic Chemotherapy: A Network Meta-analysis
por: Watanabe, Daichi, et al.
Publicado: (2022)

Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective
por: Abe, Masakazu, et al.
Publicado: (2023)

Anorexia, pain and peripheral neuropathy are associated with a decrease in quality of life in patients with advanced pancreatic cancer receiving outpatient chemotherapy — a retrospective observational study
por: Fujii, Hironori, et al.
Publicado: (2021)

A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin‐Based Chemotherapy‐Induced Nausea and Vomiting in Japan
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
por: Watanabe, Daichi, et al.
Publicado: (2023)

5HT(3)RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer
por: Hayashi, Toshinobu, et al.
Publicado: (2020)

Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy
por: Affronti, Mary Lou, et al.
Publicado: (2014)

The Role of Adjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma Patients with Pathological Positive Lymph Nodes After Neoadjuvant Chemotherapy Followed by Esophagectomy: a Single Institute Retrospective Analysis
por: Imai, Takeharu, et al.
Publicado: (2021)

Genotype frequencies for polymorphisms related to chemotherapy-induced nausea and vomiting in a Japanese population
por: Goto, Aya, et al.
Publicado: (2016)

Total laparoscopic excision of retroperitoneal ganglioneuroma: A case report
por: Kitazawa, Mai, et al.
Publicado: (2021)

Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis
por: Hayashi, Toshinobu, et al.
Publicado: (2021)

Longitudinal assessment of pain management with the pain management index in cancer outpatients receiving chemotherapy
por: Fujii, Akiko, et al.
Publicado: (2016)

Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Evaluation of histopathological heterogeneity of colorectal cancer liver metastasis sites after preoperative chemotherapy
por: Matsuhashi, Nobuhisa, et al.
Publicado: (2022)

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy
por: Navari, Rudolph M., et al.
Publicado: (2018)

Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy
por: Shimokawa, Mototsugu, et al.
Publicado: (2022)

Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Chemotherapy-Induced Nausea and Vomiting
por: Rapoport, Bernardo Leon, et al.
Publicado: (2015)

Comment on ‘risk factors associated with nausea and vomiting in children with cancer receiving chemotherapy’
por: Tong, Wing H, et al.
Publicado: (2023)

The Effect and Safety of Olanzapine on Nausea and Vomiting in Children Receiving Moderately Emetogenic Chemotherapy
por: Eghbali, Aziz, et al.
Publicado: (2023)

Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023)

Elemental diet plus glutamine for the prevention of mucositis in esophageal cancer patients receiving chemotherapy: a feasibility study
por: Tanaka, Yoshihiro, et al.
Publicado: (2015)

Chemotherapy- and cancer-related nausea and vomiting
por: Warr, D.G.
Publicado: (2008)

Erratum to: Elemental diet plus glutamine for the prevention of mucositis in esophageal cancer patients receiving chemotherapy: a feasibility study
por: Tanaka, Yoshihiro, et al.
Publicado: (2015)

Single‐dose NEPA versus an aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2023)

Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial
por: Iihara, Hirotoshi, et al.
Publicado: (2019)

Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens
por: Yoshida, Naohisa, et al.
Publicado: (2019)

A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy‐Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
por: Zelek, Laurent, et al.
Publicado: (2021)

Subtotal esophagectomy followed by subtotal gastric reconstruction for Boerhaave's syndrome: Case report with literature review
por: Tanaka, Yoshihiro, et al.
Publicado: (2021)

Individual differences in chemotherapy-induced anticipatory nausea
por: Rodríguez, Marcial
Publicado: (2013)

Management of Patients With Chemotherapy-Induced Nausea and Vomiting
por: Barbour, Sally Yowell
Publicado: (2017)

Chemotherapy-Induced Nausea and Vomiting: Updates and Recommendations
por: Viale, Pamela Hallquist
Publicado: (2018)

Open-label observational study to assess the efficacy and safety of aprepitant for chemotherapy-induced nausea and vomiting prophylaxis in Indian patients receiving chemotherapy with highly emetogenic chemotherapy/moderately emetogenic chemotherapy regimens
por: Hingmire, Sachin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rhljfliemvctt9vdjcrtrfghva